NASDAQ:QDEL - Nasdaq - US2197981051 - Common Stock - Currency: USD
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - imaging, diagnostics stocks fared in Q4, starting with Hologic (NASDAQ:HOLX).
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including QuidelOrtho (NASDAQ:QDEL) and its peers.
Over the last six months, QuidelOrtho’s shares have sunk to $40.10, producing a disappointing 7.7% loss - a stark contrast to the S&P 500’s 7.1% gain. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) reported Q4 CY2024 results topping the market’s revenue expectations, but sales fell by 4.7% year on year to $707.8 million. On the other hand, the company’s full-year revenue guidance of $2.71 billion at the midpoint came in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.63 per share was 8.5% above analysts’ consensus estimates.
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) will be announcing earnings results tomorrow afternoon. Here’s what to expect.
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ:...
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ:...